Study of hypoglycemic properties of «Glyphasonorm» tablets and «Glyphasolin» capsules on the streptozotocin-induced diabetic rat model

Authors

DOI:

https://doi.org/10.15587/2519-4852.2022.271034

Keywords:

streptozotocin-induced diabetes, hypoglycemic activity, glycosylated haemoglobin, metformin, «Glyphasonorm» tablets, «Glyphasolin» capsules

Abstract

The risk of developing any complications of diabetes is significantly reduced by monitoring and correcting blood glucose levels and blood pressure, as well as by observing healthy lifestyle rules. Early detection and treatment of type 2 diabetes contribute to the prevention of disease progression and the development of complications.

The aim is to study the hypoglycemic effect of «Glyphasonorm» tablets and «Glyphasolin» capsules in a rat model of streptozotocin-induced diabetes.

Materials and methods. The studies were carried out on Wistar rats injected intraperitoneally with nicotinamide at a dose of 230 mg/kg 15 minutes before intravenous injection of streptozotocin at a dose of 65 mg/kg. The dynamics of body weight of rats, glucose and glycosylated haemoglobin levels under the impact of long-term administration of metformin, «Glyphasonorm» tablets and «Glyphasolin» capsules were investigated.

Results and discussion. The studies on a streptozotocin-induced diabetic model have established that under the action of «Glyphasonorm» tablets and «Glyphasolin» capsules, the level of glycosylated haemoglobin, which decreased along with the level of glucose in the blood of animals, was significantly reduced in comparison with diabetic control. After 14 days of research, the "Glyphasolin" capsules showed more pronounced hypoglycemic activity (4.4 % and 8.0 % more) than the "Glyphasonorm" tablets and the reference drug metformin. The «Glyphasolin» capsules on the 12th day of the study showed a marked decrease in glycosylated haemoglobin in the blood of animals (3.1 % and 5.6 % more) than the «Glyphasonorm» tablets and metformin.

Conclusions. In the experimental model of streptozotocin diabetes in rats, "Gliphasolin" capsules showed a more pronounced hypoglycemic effect, which was manifested by a decrease in the content of glycosylated haemoglobin in the blood and prevailed over the effect of the comparative drug metformin and "Gliphasonorm" tablets.

«Glyphasolin» capsules and «Glyphasonorm» tablets based on bioflavonoid complex from bean show promise in the treatment of type 2 diabetes on the background of obesity and reducing the risk of micro- and macroangiopathy

Author Biographies

Viktoria Rybak, National University of Pharmacy

Doctor of Biological Sciences, Professor

Department of Physiology and Pathological Physiology

Alexander Honcharov, National University of Pharmacy

PhD, Assistant

Department of Pharmacognosy

Viktoriia Korol, National University of Pharmacy

PhD, Associate Professor

Department of Chemistry of Natural Compounds and Nutrition

References

  1. Nathan, D. M., Buse, J. B., Davidson, M. B. et al. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care, 32. doi: https://doi.org/10.2337/dc09-0271
  2. Rybak, V. A., Maloshtan, L. M. (2014). Vykorystannia bioflavonoidnoho kompleksu z kvasoli dlia likuvannia metabolichnoho syndromu na tli ozhyrinnia. Inform. lyst pro novovvedennia v systemi okhorony zdorov’ia No. 279. Kyiv, 35, 4.
  3. Dedov, I. I., Shestakova, M. V. (2003). Sakharnyi diabet. Moscow, 455.
  4. Dedov, I. I., Shestakova, M. V. (Eds.) (2009). Algoritm spetcializirovannoi meditcinskoi pomoshchi bolnym sakharnym diabetom. Moscow, 103.
  5. Bogachev, V. Yu., Golovanova, O. V., Kuznetsov, A. N., Shekoayan, A. O. (2013). Bioflavonoids and their significance in angiology: focus on diosmi. Angiology and vascular surgery, 19 (1), 73–81.
  6. Rybak, V. A. (2014). Determination of the effective dose (ED50) of spissum bean extract with potential hypoglycemic propertie. Problemy ekolohichnoi ta medychnoi henetyky i klinichnoi imunolohii, 1 (121), 225–230.
  7. Rybak, V. A., Maloshtan, L. M., Poltorak, V. V., Krasova, N. S. (2015). Vplyv tryvaloho zastosuvannia hustoho ekstraktu kvasoli na dynamiku masy tila, masy fraktsii abdominalnoi zhyrovoi tkanyny u shchuriv z tsukrovym diabetom 2-ho typu na tli ozhyrinnia. Svit medytsyny ta biolohii, 2 (50), 172–175.
  8. Rieznykov, O. H. (2003). Zahalni etychni pryntsypy eksperymentiv na tvarynakh. Endokrynolohiia, 8 (1), 142–145.
  9. Stefanov, O. V. (Ed.) Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena, 528.
  10. Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 40 (4), 405–412. https://doi.org/10.2337/diabetes.40.4.405
  11. Rybolovlev, Iu. R. (1979). Dozirovanie veshchestv dlia mlekopitaiushchikh po konstante biologicheskoi aktivnosti. Zhurnal AN SSSR, 247 (6), 1513–1516.
  12. Nazarenko, G. I., Kishkun, A. A. (2002). Klinicheskaia otcenka rezultatov laboratornykh analizov. Moscow: Meditcina, 544.
  13. Rybak, V. A., Maloshtan, L. M., Poltorak, V. V., Krasova, N. S. (2015). Vyvchennia antyoksydantnykh vlastyvostei hustoho ekstraktu kvasoli na modeli tsukrovoho diabetu 2-ho typu na tli ozhyrinnia v shchuriv. Farmakolohiia ta likarska toksykolohiia, 1 (42), 76–81.
  14. Patel A., MacMahon S., Chalmers J. et al. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358, 2560–2572. doi: https://doi.org/10.1056/nejmoa0802987
  15. Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M. et al. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care, 32 (1), 187–192. doi: https://doi.org/10.2337/dc08-9026
  16. Gerstein, H. C., Miller, M. E., Byington, R. P. et al. (2008). Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 358 (24), 2545–2559. doi: https://doi.org/10.1056/nejmoa0802743
  17. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration (2007). Diabetologia, 50 (6), 1140–1147. doi: https://doi.org/10.1007/s00125-007-0599-y
  18. Voloshin, O. I., Glubochenko, O. V., Pankiv, I. V., Glubochenko, V. G., Malkovich, N. M. (2021). Peculiarities of phytotherapy of diabetes mellitus through the prism of comorbidity and prevention of complications (review of literature). International Journal of Endocrinology (Ukraine), 15 (3), 258–267. doi: https://doi.org/10.22141/2224-0721.15.3.2019.172113
  19. Kurylo, Kh. I., Klishch, I. M., Volska, A. S., Barchuk, O. Z. (2016). Research of hypoglycemic properties of dry extract of vaccinium myrtillus L. Medical and Clinical Chemistry, 18 (2), 38–41. doi: https://doi.org/10.11603/mcch.2410-681x.2016.v0.i2.6669
  20. Kurylo, Kh. I., Klishch, I. M., Volska, A. S., Rozhkovskyi, Ya. V. (2020). Investigation of the influence of phytocompositions on the process of non-permanent glycosylation, activity of cytolytic processes, indicators of lipid exchange and lipid peroxidation balance in animal’s body in experimental diabetes. Medical and Clinical Chemistry, 4, 162–168. doi: https://doi.org/10.11603/mcch.2410-681x.2019.v.i4.10854

Downloads

Published

2022-12-30

How to Cite

Rybak, V., Honcharov, A., & Korol, V. (2022). Study of hypoglycemic properties of «Glyphasonorm» tablets and «Glyphasolin» capsules on the streptozotocin-induced diabetic rat model. ScienceRise: Pharmaceutical Science, (6(40), 51–57. https://doi.org/10.15587/2519-4852.2022.271034

Issue

No. 6(40) (2022)

Section

Pharmaceutical Science

License

Copyright (c) 2022 Viktoria Rybak, Alexander Honcharov, Viktoriia Korol

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.